Piper Sandler downgraded Supernus to Neutral from Overweight with a price target of $36, down from $41.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus announces FDA acceptance of SPN-830 apomorphine infusion device NDA
- Supernus raises 2024 sales outlook to $600M-$625M from $580M-$620M
- Supernus reports Q2 adjusted operating earnings $45.5M vs. $10M last year